Hospital pharmacy organization, law and professional ethics (Swissmedic, HMG, BetmVV, formulary governance)
This domain tests whether you can place everyday hospital pharmacy work - manufacturing, dispensing, formulary decisions, data handling - inside the Swiss legal framework, and whether you can argue an ethical position instead of reciting rules.
The legal layers you must keep apart
- HMG (SR 812.21) regulates medicinal products: authorisation, manufacture, dispensing, advertising and vigilance. Swissmedic enforces it federally and issues GMP requirements, monographs and recall notices.
- The cantonal operating licence (Betriebsbewilligung) authorises the pharmacy's activity; manufacturing additionally requires an HMG Art. 5 authorisation and a named fachtechnisch verantwortliche Person under the Arzneimittelverordnung (VAM).
- Prescription law: medicinal products are prescription-only unless classified otherwise (HMG Art. 26). Narcotics sit under BetmG, with the substance schedules of BetmVV-EDI and the control duties of BetmKV.
- Ph. Helv. supplies the binding monographs for preparations made in-house.
Formulary governance
A defensible Arzneimittelkommission decision records: indication and comparator, strength of evidence (hard endpoints before surrogates), place in therapy, cost and budget impact, safety, and handling requirements (cold chain, narcotic, cytotoxic). Restricted-use categories, a fixed re-evaluation date and a documented appeal route turn a preference into governance. Off-label or unlicensed use needs a written justification, a named responsible physician and a documented risk–benefit consideration; your job is to make that reasoning visible, not to veto silently.
Ethics in practice
Confidentiality (Art. 321 StGB), patient autonomy and informed consent, the Human Research Act (HFG) for studies with human material, and transparent handling of conflicts of interest recur throughout. Ethical conflict usually shows up as scarcity, end-of-life deprescribing, or pressure from a senior clinician - the exam wants structured reasoning, not a verdict.
Worked example
A clinic requests a new oncology agent for second-line use: weak phase II data, no overall-survival benefit, CHF 90,000 per patient-year. Reasoning: low evidence level → conditional approval restricted to a defined patient group, a registry to capture outcomes, re-evaluation after 12 months, and an explicit note that funding approval is not a clinical recommendation. That earns marks; "the AMK rejects it" earns few.
Traps
- Confusing Swissmedic marketing authorisation with hospital formulary inclusion - separate decisions, separate bodies.
- Mixing BetmG, BetmVV-EDI and BetmKV; know which instrument does what.
- Treating cantonal rules as uniform (narcotic prescriptions, emergency dispensing, hospital licences differ).
- An undocumented but correct ethical decision scores as if it had not been made.